# Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

> **NCT02191059** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 60 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02191059
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2015-07
- **Final completion:** 2016-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191059, "Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02191059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*